Impact of physiological, and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans

被引:100
作者
Hurst, Susan [1 ]
Loi, Cho-Ming [1 ]
Brodfuehrer, Joanne [1 ]
El-Kattan, Ayman [1 ]
机构
[1] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Ann Arbor, MI 48105 USA
关键词
absorption; bioavailability; biopharmaceutical factors; first-pass effect; metabolism; physicochemical factors; species differences;
D O I
10.1517/17425225.3.4.469
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The onset, intensity and duration of therapeutic response to a compound depend on the intrinsic pharmacological activity of the drug and pharmacokinetic factors related to its absorption, distribution, metabolism and elimination that are inherent to the biological system. The process of drug transfer from the site of administration to the systemic circulation and the interspecies factors that impact this process are the scope of this review. In general, the factors that influence oral drug bioavailability via absorption and metabolism can be divided into physicochemical/biopharmaceutical and physiological factors. Physicochemical and biopharmaceutical factors that influence permeability and solubility tend to be species independent. Although there are significant differences in the anatomy and physiology of the gastrointestinal tract, these are not associated with significant differences in the rate and extent of drug absorption between rats and humans. However, species differences in drug metabolism in rats and humans did result in significant species differences in bioavailability. Overall, this review provides a better understanding of the interplay between drug physicochemical/biopharmaceuticaI factors and species differences/similarities in the absorption and metabolism mechanisms that affect oral bioavailability in rats and humans. This will enable a more rational approach to perform projection of oral bioavailability in human using available rat in vivo data.
引用
收藏
页码:469 / 489
页数:21
相关论文
共 189 条
[1]   Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man [J].
Abel, S ;
Beaumont, KC ;
Crespi, CL ;
Eve, MD ;
Fox, L ;
Hyland, R ;
Jones, BC ;
Muirhead, GJ ;
Smith, DA ;
Venn, RF ;
Walker, DK .
XENOBIOTICA, 2001, 31 (8-9) :665-676
[2]  
ABRAHAMSSON B, 2005, DRUG BIOAVAILABILITY, P495
[3]   Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques [J].
Avdeef, A ;
Testa, B .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (10) :1681-1689
[4]  
Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100
[5]   CLINICAL PHARMACOKINETICS IN VETERINARY-MEDICINE [J].
BAGGOT, JD .
CLINICAL PHARMACOKINETICS, 1992, 22 (04) :254-273
[6]   Grapefruit juice felodipine interaction:: Effect of naringin and 6′,7′-dihydroxybergamottin in humans [J].
Bailey, DG ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :248-256
[7]   The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery [J].
Bardelmeijer, HA ;
van Tellingen, O ;
Schellens, JHM ;
Beijnen, JH .
INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) :231-241
[8]   Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist [J].
Beaumont, K ;
Webster, R ;
Gardner, I ;
Dack, K .
CURRENT DRUG METABOLISM, 2003, 4 (06) :461-485
[9]   CLINICAL PHARMACOKINETICS OF LIGNOCAINE [J].
BENOWITZ, NL ;
MEISTER, W .
CLINICAL PHARMACOKINETICS, 1978, 3 (03) :177-201
[10]   PHARMACEUTICAL SALTS [J].
BERGE, SM ;
BIGHLEY, LD ;
MONKHOUSE, DC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (01) :1-19